PRISM-xQTL:与系统级多原子QTL分析集成的类关系,用于在阿尔茨海默病中寻找因果基因和分子媒介
Nitesh Enduru1,2, Zhongming Zhao1,3
1Center for Precision Health, McWilliams School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, Texas, USA.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|January 29, 2026
概括
这项研究介绍了PRISM-xQTL,这是阿尔茨海默病 (AD) 遗传研究的新型框架. 它将非编码风险变体与免疫调节联系起来,并确定像FCER1G.这样的潜在治疗点.
科学领域:
- 遗传学 是一个遗传学.
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
背景情况:
- 大多数阿尔茨海默病 (AD) 风险变体都存在于非编码DNA中,因此很难确定它们的因果作用.
- 了解基因调节对于开发有效的AD治疗至关重要.
研究的目的:
- 开发一个多原子框架,PRISM-xQTL,用于剖析AD中的遗传调节.
- 为了整合多种定量特征位点 (QTLs) 的类型,共同定位,门德尔随机化和调解分析.
- 为了确定非编码变体,免疫机制和AD风险之间的因果关系.
主要方法:
- 开发了PRISM-xQTL (与系统级多原子QTL集成的类关系) 框架.
- 集成的多原子 QTL 数据 (eQTL,meQTL,sQTL,pQTL,sc-eQTL) 具有 pleiotropy,同定位,门德尔随机化和调解分析.
- 用AlphaGenome和阿尔茨海默氏病细胞图谱 (TACA) 进行功能验证,分析了70种常见于AD和11种免疫障碍的单核酸多态 (SNPs).
主要成果:
- 在54个基因型-组织表达 (GTEx) 组织中确定了410个SNP-基因-组织共定位.
- 在FCER1G.发现SNP rs4233366与表达QTL (eQTL) 和甲基化QTL (meQTL) 信号共定位在FCER1G.
- 门德尔的随机化和调解分析表明,CpG位点通过FCER1G影响AD风险,AlphaGenome验证了FCER1G的调节作用和治疗相关性.
结论:
- PRISM-xQTL有效地改进了对非编码AD风险变体的因果推理.
- 突出了免疫调节机制在AD病变发生过程中的作用.
- 优先考虑FCER1G作为阿尔茨海默病的潜在治疗点.
相关概念视频
Pleiotropy
31.3K
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
31.3K
Pharmacogenomics: Identification of New Drug Targets
129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129


